<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article206</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/Prednisolone_in_Severe_Alcoholic_Hepatitis" style="display:block; margin-bottom:10px;">Prednisolone in Severe Alcoholic Hepatitis Original</a></li>
<h2><strong>Prednisolone in Severe Alcoholic Hepatitis</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Corticosteroids in the Treatment of Severe Alcoholic Hepatitis". The New England Journal of Medicine. 1992. 326(8):507-512. PubMed • Full text • PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients with severe alcoholic hepatitis, does treatment with prednisolone improve short-term survival?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Treatment with prednisolone significantly improves short-term survival in patients with severe biopsy-proved alcoholic hepatitis.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
The efficacy of corticosteroids in the treatment of alcoholic hepatitis has been inconsistent in controlled trials. This study aimed to re-evaluate the hypothesis that corticosteroids could improve short-term survival in patients with severe alcoholic hepatitis, identified by discriminant-function value or spontaneous hepatic encephalopathy.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of the last knowledge update, specific guidelines reflecting the results of this trial concerning the management of severe alcoholic hepatitis with corticosteroids could not be provided.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
- Randomized, double-blind, placebo-controlled trial<br/>
- N=61 patients with biopsy-proved alcoholic hepatitis<br/>
- Prednisolone (40 mg per day) vs placebo<br/>
- Setting: Two medical centers<br/>
- Enrollment: March 1987 to June 1990<br/>
- Primary endpoint: Death within two months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria<br/>
- Long-standing history of alcoholism<br/>
- Clinical features of alcoholic hepatitis<br/>
- Biopsy-proved alcoholic hepatitis<br/>
- Spontaneous hepatic encephalopathy or discriminant-function value higher than 32<br/>
<br/>
Exclusion Criteria<br/>
- Gastrointestinal bleeding or bacterial infection not controlled within 48 hours<br/>
<br/>
Baseline Characteristics<br/>
- 57 patients had evidence of cirrhosis on biopsy<br/>
- 4 patients had alcoholic hepatitis and fibrosis<br/>
- Mean follow-up: Not specified<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
- Randomized to either prednisolone 40 mg or placebo, given as a single morning dose for 28 days<br/>
- Patients unable to take oral medication received prednisolone or placebo intravenously<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
- At day 66 post-randomization, survival was 88±5 percent in the prednisolone group vs 45±8 percent in the placebo group (log-rank test, 10.9; P=0.001)<br/>
<br/>
Secondary Outcomes<br/>
- At six months post-enrollment, cumulative survival rates were 84±6 percent for prednisolone vs 45±9 percent for placebo (log-rank test, 9.5; P=0.002)<br/>
- No major adverse effects related to corticosteroid therapy were observed<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
- Not specified<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
- More details and analysis can be found in the full text of the study
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
